Association between prediabetes and breast cancer: a comprehensive meta-analysis.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI:10.1007/s10549-023-07181-x
Praneeth Reddy Keesari, Akhil Jain, Narendranath Reddy Ganampet, Guna Sowmya Durga Subhasri, Samuel Edusa, Zainab Muslehuddin, Nyein Wint Yee Theik, Spandana Palisetti, Divya Salibindla, Pritika Singh Manaktala, Rupak Desai
{"title":"Association between prediabetes and breast cancer: a comprehensive meta-analysis.","authors":"Praneeth Reddy Keesari, Akhil Jain, Narendranath Reddy Ganampet, Guna Sowmya Durga Subhasri, Samuel Edusa, Zainab Muslehuddin, Nyein Wint Yee Theik, Spandana Palisetti, Divya Salibindla, Pritika Singh Manaktala, Rupak Desai","doi":"10.1007/s10549-023-07181-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer accounts for up to 30% of cancer cases in women in the US. Diabetes mellitus has been recognized as a risk factor for breast cancer. Some studies have suggested that prediabetes may also be associated with breast cancer whereas other studies have shown no or an inverse association; thus, we conducted a meta-analysis to assess the risk of breast cancer in prediabetes.</p><p><strong>Methods: </strong>We searched PubMed/Medline, EMBASE, Google Scholar, and Scopus to identify studies that reported breast cancer risks in patients having prediabetes compared to normoglycemic patients. Binary random-effects model was used to calculate a pooled odds ratio (OR) with 95% confidence intervals. I<sup>2</sup> statistics were used to assess heterogeneity. Leave-one-out sensitivity analysis and subgroup analyses were performed.</p><p><strong>Results: </strong>We analyzed 7 studies with 24,586 prediabetic and 224,314 normoglycemic individuals (783 and 5739 breast cancer cases, respectively). Unadjusted odds ratio (OR) for breast cancer was 1.45 (95% CI = 1.14, 1.83); adjusted OR was 1.19 (95% CI = 1.07, 1.34) in prediabetes. Subgroup analysis revealed a higher breast cancer risk in individuals aged less than 60 years (OR = 1.86, 95% CI = 1.39, 2.49) than in those aged 60 years or more (OR = 1.07, 95% CI = 0.97, 1.18). Subgroup analysis by median follow-up length indicated a higher risk of breast cancer for follow-ups of less than or equal to 2 years (OR = 2.34, 95% CI = 1.85, 2.95) than in those of over 10 years (OR = 1.1, 95% CI = 0.99, 1.23) and 6 to 10 years (OR = 1.03, 95% CI = 0.88, 1.21).</p><p><strong>Conclusions: </strong>In conclusion, individuals with prediabetes have higher risk of developing breast cancer than those with normoglycemia, especially younger prediabetes patients. These individuals may benefit from early identification, monitoring, and interventions to reverse prediabetes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"1-13"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-023-07181-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer accounts for up to 30% of cancer cases in women in the US. Diabetes mellitus has been recognized as a risk factor for breast cancer. Some studies have suggested that prediabetes may also be associated with breast cancer whereas other studies have shown no or an inverse association; thus, we conducted a meta-analysis to assess the risk of breast cancer in prediabetes.

Methods: We searched PubMed/Medline, EMBASE, Google Scholar, and Scopus to identify studies that reported breast cancer risks in patients having prediabetes compared to normoglycemic patients. Binary random-effects model was used to calculate a pooled odds ratio (OR) with 95% confidence intervals. I2 statistics were used to assess heterogeneity. Leave-one-out sensitivity analysis and subgroup analyses were performed.

Results: We analyzed 7 studies with 24,586 prediabetic and 224,314 normoglycemic individuals (783 and 5739 breast cancer cases, respectively). Unadjusted odds ratio (OR) for breast cancer was 1.45 (95% CI = 1.14, 1.83); adjusted OR was 1.19 (95% CI = 1.07, 1.34) in prediabetes. Subgroup analysis revealed a higher breast cancer risk in individuals aged less than 60 years (OR = 1.86, 95% CI = 1.39, 2.49) than in those aged 60 years or more (OR = 1.07, 95% CI = 0.97, 1.18). Subgroup analysis by median follow-up length indicated a higher risk of breast cancer for follow-ups of less than or equal to 2 years (OR = 2.34, 95% CI = 1.85, 2.95) than in those of over 10 years (OR = 1.1, 95% CI = 0.99, 1.23) and 6 to 10 years (OR = 1.03, 95% CI = 0.88, 1.21).

Conclusions: In conclusion, individuals with prediabetes have higher risk of developing breast cancer than those with normoglycemia, especially younger prediabetes patients. These individuals may benefit from early identification, monitoring, and interventions to reverse prediabetes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
前驱糖尿病与乳腺癌之间的关系:一项综合荟萃分析。
背景:乳腺癌占美国女性癌症病例的30%。糖尿病已被认为是乳腺癌的一个危险因素。一些研究表明前驱糖尿病也可能与乳腺癌有关而另一些研究则没有显示出相关或呈负相关;因此,我们进行了一项荟萃分析来评估前驱糖尿病患者患乳腺癌的风险。方法:我们检索了PubMed/Medline、EMBASE、Google Scholar和Scopus,以确定与血糖正常患者相比,前驱糖尿病患者患乳腺癌风险的研究。采用二元随机效应模型计算95%置信区间的合并优势比(OR)。采用I2统计来评估异质性。进行留一敏感性分析和亚组分析。结果:我们分析了7项研究,涉及24,586名糖尿病前期患者和224,314名血糖正常者(分别为783例和5739例乳腺癌患者)。乳腺癌的未调整优势比(OR)为1.45 (95% CI = 1.14, 1.83);糖尿病前期校正OR为1.19 (95% CI = 1.07, 1.34)。亚组分析显示,60岁以下人群患乳腺癌的风险(OR = 1.86, 95% CI = 1.39, 2.49)高于60岁及以上人群(OR = 1.07, 95% CI = 0.97, 1.18)。按中位随访时间进行的亚组分析显示,随访时间少于或等于2年(or = 2.34, 95% CI = 1.85, 2.95)的乳腺癌风险高于随访时间超过10年(or = 1.1, 95% CI = 0.99, 1.23)和6至10年(or = 1.03, 95% CI = 0.88, 1.21)的乳腺癌风险。结论:总之,糖尿病前期患者发生乳腺癌的风险高于血糖正常的患者,尤其是年轻的糖尿病前期患者。这些人可能受益于早期识别、监测和干预,以逆转前驱糖尿病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor. Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population. Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health. Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy. Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1